跳至主要内容
临床试验/NCT00310687
NCT00310687已完成4 期

A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign

Novartis2 个研究点 分布在 1 个国家目标入组 1,244 人开始时间: 2004年10月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
Novartis
入组人数
1,244
试验地点
2
主要终点
persistence of memory response to N. meningitidis serogroup C as measured by serum bactericidal activity at one year after either a challenge with 1/5 of a dose of Meningococcal A/C Polysaccharide vaccine or a booster dose of MenC Vaccine.

研究概览

简要总结

Persistence of Immune response after vaccination with MCC

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
11 Years 至 20 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • healthy adolescents vaccinated with Meningococcal C Conjugate vaccine

排除标准

  • ascertained or suspected disease caused by N. meningitidis
  • household contact with individuals with proven N. meningitidis serogroup C infection
  • significant acute or chronic infections
  • any other serious disease

结局指标

主要结局

persistence of memory response to N. meningitidis serogroup C as measured by serum bactericidal activity at one year after either a challenge with 1/5 of a dose of Meningococcal A/C Polysaccharide vaccine or a booster dose of MenC Vaccine.

次要结局

  • Evaluation of the immunological response (ELISA) to N. meningitidis serogroup C
  • Evaluation and comparison of the persistence of antibodies against N. meningitidis serogroup C as measured by hBCA

研究者

发起方
Novartis
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验